Published in Biochem Pharmacol on May 15, 1975
Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci U S A (1993) 2.08
Aging decreases L-type calcium channel currents and pacemaker firing fidelity in substantia nigra dopamine neurons. J Neurosci (2014) 1.46
Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage (2009) 1.24
Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease. J Neurosci (2016) 0.79
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med (1988) 4.98
Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev (1966) 4.55
Dopa-responsive dystonia: pathological and biochemical observations in a case. Ann Neurol (1994) 2.88
Cortical-basal ganglionic degeneration. Neurology (1990) 2.04
Biochemical pathophysiology of Parkinson's disease. Adv Neurol (1987) 1.87
Kainic acid induced seizures: neurochemical and histopathological changes. Neuroscience (1983) 1.75
Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions. Science (1970) 1.62
Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice. Eur J Pharmacol (1974) 1.60
Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature (1978) 1.52
Technetium-99m-d,1-hexamethylpropyleneamine oxime (HMPAO) uptake and glutathione content in brain tumors. J Nucl Med (1991) 1.48
Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med (1981) 1.48
Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Br Med Bull (1973) 1.47
Brain neurotransmitter changes in three patients who had a fatal hyperthermia syndrome. Am J Psychiatry (1990) 1.43
The mechanisms of action of L-dopa in Parkinson's disease. Life Sci (1974) 1.42
Hereditary form of parkinsonism--dementia. Ann Neurol (1998) 1.39
Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol (1982) 1.36
Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol (1995) 1.34
Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology (1996) 1.30
The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther (1975) 1.28
[Homovanillic acid in the cerebrospinal fluid: studies in Parkinson's syndrome and other diseases of the CNS]. Wien Klin Wochenschr (1966) 1.26
Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology (2008) 1.22
Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology (1998) 1.19
Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia. Neurology (1999) 1.16
Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur J Pharmacol (1972) 1.14
Parkinson's disease: from brain homogenate to treatment. Fed Proc (1973) 1.14
Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem (1992) 1.13
Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry (2001) 1.12
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience (1991) 1.12
Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation. Neurology (2000) 1.05
GTP-cyclohydrolase I gene mutations in hereditary progressive amd dopa-responsive dystonia. Ann Neurol (1996) 1.04
Brain neurotransmitters in dystonia musculorum deformans. N Engl J Med (1986) 1.00
Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser (1975) 1.00
Kainic acid-induced seizures: dose-relationship of behavioural, neurochemical and histopathological changes. Brain Res (1985) 1.00
A model for the quantitative study of central dopaminergic and serotoninergic activity. Eur J Pharmacol (1972) 0.99
Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res (1994) 0.97
Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine. Adv Biochem Psychopharmacol (1978) 0.97
Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol (1985) 0.96
Kainic acid-induced changes of serotonin and dopamine metabolism in the striatum and substantia nigra of the rat. Eur J Pharmacol (1981) 0.96
Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients. Adv Biochem Psychopharmacol (1974) 0.96
The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord (1998) 0.96
Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett (1985) 0.95
L-glutamic acid decarboxylase in Parkinson's disease: effect of L-dopa therapy. Nature (1973) 0.95
Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Ann Neurol (1995) 0.93
The cyclooxygenase and lipoxygenase inhibitor BW755C protects rats against kainic acid-induced seizures and neurotoxicity. Brain Res (1994) 0.92
Dementia, parkinsonism, and motor neuron disease: neurochemical and neuropathological correlates. Ann Neurol (1988) 0.92
Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation. J Neurol Sci (1973) 0.91
Cerebral cortex Gs alpha protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem (1993) 0.90
Occurrence and distribution of L-DOPA decarboxylase in the human brain. Brain Res (1970) 0.90
Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence. Annu Rev Pharmacol Toxicol (1977) 0.90
The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett (1988) 0.89
Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat Disord (1998) 0.89
Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Ann Neurol (1987) 0.89
The role of brain edema in epileptic brain damage induced by systemic kainic acid injection. Neuroscience (1984) 0.88
[Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism]. Klin Wochenschr (1965) 0.88
Beneficial effects of serotonin precursors in postanoxic action myoclonus. Neurology (1976) 0.87
Neurochemical pathology and pharmacology of brain dopamine and acetylcholine: rational basis for the current drug treatment of Parkinsonism. Contemp Neurol Ser (1971) 0.87
Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease. J Neurochem (1992) 0.87
Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. J Neurochem (1972) 0.87
Imbalance of brain monoamines and clinical disorders. Prog Brain Res (1982) 0.86
Distribution of high affinity sodium-independent [3H]gamma-aminobutyric acid [3H]GABA binding in the human brain: alterations in Parkinson's disease. Brain Res (1977) 0.86
Neurochemical basis of dementia in Parkinson's disease. Can J Neurol Sci (1984) 0.86
Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann Neurol (1986) 0.86
Brain neurotransmitter changes in human narcolepsy. Neurology (1992) 0.85
Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. FASEB J (2001) 0.85
Noradrenaline distribution insubcortical areas of the human brain. Brain Res (1977) 0.85
[3H]vesamicol binding in human brain cholinergic deficiency disorders. Neurosci Lett (1990) 0.85
Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice. Neuroscience (2011) 0.85
Neurohumoral interactions and basal ganglia function and dysfunction. Res Publ Assoc Res Nerv Ment Dis (1976) 0.85
[Dopamine metabolism in the rabbit caudate nucleus following partial inhibition of brain monoamine oxidase by nialamide]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 0.85
Cerebellar norepinephrine in patients with Parkinson's disease and control subjects. Arch Neurol (1984) 0.85
Dopamine in thelimbic regions of the human brain: normal and abnormal. Adv Biochem Psychopharmacol (1977) 0.84
[The influence of diethyldithiocarbamate on cerebral catecholamine, spontaneous activity and L-DOPA hyperactivity]. Med Pharmacol Exp Int J Exp Med (1967) 0.84
Down's syndrome individuals begin life with normal levels of brain cholinergic markers. J Neurochem (1989) 0.84
Brain glutathione peroxidase in neurodegenerative disorders. Neurochem Pathol (1986) 0.84
Role of glucocorticoids in the cholinergic degeneration in rat hippocampus induced by ethylcholine aziridinium (AF64A). J Neurosci (1993) 0.84
The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study. Neurobiol Dis (2012) 0.84
L-DOPA treatment in Parkinson's disease: effect on dopamine and related substances in discrete brain regions. Experientia (1971) 0.84
Evidence for neuronal localization of histamine-N-methyltransferase in rat brain. J Neurochem (1981) 0.84
[On the diagnostic value of homovanillic acid in the cerebrospinal fluid]. Wien Klin Wochenschr (1967) 0.83
Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurochem Int (1990) 0.83
The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment. Eur J Pharmacol (1986) 0.83
Neurochemical pathology and the etiology of Parkinson's disease: basic facts and hypothetical possibilities. Mt Sinai J Med (1988) 0.82
Dopamine and extrapyramidal motor function and dysfunction. Res Publ Assoc Res Nerv Ment Dis (1972) 0.82
Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain. Science (1978) 0.82
Some mechanisms of brain edema studied in a kainic acid model. Acta Neurobiol Exp (Wars) (1990) 0.82
Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord. Brain Res (1991) 0.82
Effect of mannitol treatment on brain neurotransmitter markers in kainic acid-induced epilepsy. Neuroscience (1987) 0.81
Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter. J Pharmacol Exp Ther (1996) 0.81
Cholinergic markers in ALS spinal cord. J Neurol Sci (1992) 0.81
Brain monoamines and Parkinsonism. Psychopharmacol Bull (1975) 0.81
Amyotrophic lateral sclerosis: glutamate dehydrogenase and transmitter amino acids in the spinal cord. J Neurol Neurosurg Psychiatry (1991) 0.81
Functional sensitization of striatal dopamine D1 receptors in the 6-hydroxydopamine-lesioned rat. Brain Res (1992) 0.81
The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. Wien Klin Wochenschr (2001) 0.80
Striatal ganglioside levels in the rat following kainic acid lesions: comparison with Huntington's disease. Exp Brain Res (1981) 0.80
GABA-dopamine relationship in Parkinson's disease striatum. Adv Neurol (1987) 0.79
Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence. Neuroscience (1978) 0.79
Pharmacology and pathophysiology of dopaminergic neurons. Adv Cytopharmacol (1971) 0.79
Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy. Mov Disord (1995) 0.79
Alpha 2-adrenoceptors modulate kainic acid-induced limbic seizures. Eur J Pharmacol (1985) 0.79